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Abstract
Background: Patients with very long chain acyl-CoA dehydrogenase deficiency
(VLCADD), a long chain fatty acid oxidation disorder, are traditionally treated
with a long chain triglyceride (LCT) restricted and medium chain triglyceride
(MCT) supplemented diet. Introduction of VLCADD in newborn screening (NBS)
programs has led to the identification of asymptomatic newborns with VLCADD,
who may have a more attenuated phenotype and may not need dietary adjustments.
Objective: To define dietary strategies for individuals with VLCADD based on the
predicted phenotype.
Method: We evaluated long-term dietary histories of a cohort of individuals diag-
nosed with VLCADD identified before the introduction of VLCADD in NBS and
their beta-oxidation (LC-FAO) flux score (rate of oleate oxidation) in cultured skin
fibroblasts in relation to the clinical outcome. Based on these results a dietary strat-
egy is proposed.
Results: Sixteen individuals with VLCADD were included. One had an LC-FAO
flux score >90%, was not on a restricted diet and is asymptomatic to date. Four
patients had an LC-FAO flux score <10%, and significant VLCADD related symp-
toms despite the use of strict diets including LCT restriction, MCT supplementa-
tion and nocturnal gastric drip feeding. Patients with an LC-FAO flux score
between 10 and 90% (n = 11) showed a more heterogeneous phenotype.
Conclusions: This study shows that a strict diet cannot prevent poor clinical out-
come in severely affected patients and that the LC-FAO flux is a good predictor of
clinical outcome in individuals with VLCADD identified before its introduction in
NBS. Hereby, we propose an individualized dietary strategy based on the LC-FAO
flux score.
Jeannette C. Bleeker and Irene L. Kok contributed equally to this work.
DOI: 10.1002/jimd.12037
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original
work is properly cited.
© 2018 The Authors. Journal of Inherited Metabolic Disease published by John Wiley & Sons Ltd on behalf of SSIEM
J Inherit Metab Dis. 2019;42:159–168. wileyonlinelibrary.com/journal/jimd 159
Correspondence
Gepke Visser, Wilhelmina Children’s
Hospital (UMCU), Internal mail KE
04.306.0, PO Box 85090, 3508 AB Utrecht,
Netherlands.
Email: gvisser4@umcutrecht.nl
Communicated By: Avihu Boneh
1 | INTRODUCTION
Very long chain acyl-CoA dehydrogenase deficiency
(VLCADD) is an autosomal recessive inherited disorder of
mitochondrial long-chain fatty acid beta-oxidation (OMIM
201475) in which energy homeostasis is compromised and
toxic intermediates accumulate. Patients may present with
hypoglycemia, rhabdomyolysis, hepatomegaly, and (cardio)
myopathy.1–6 Traditionally, treatment of VLCADD is aimed
at preventing catabolism by avoidance of fasting.7,8 In addi-
tion, a long chain triglycerides (LCT) restricted diet, supple-
mented with medium chain triglycerides (MCT), is generally
advised in order to bypass long chain fatty acid oxidation for
energy production.7–11
In the past few decades, VLCADD has been incorporated
into newborn screening (NBS) programs in many countries
worldwide. This has resulted in the detection of individuals
with a diagnosis of VLCADD confirmed by molecular
and/or enzymatic studies that are asymptomatic or have less
severe phenotypes. It has been suggested that patients with
less severe phenotypes might be treated by avoidance of
long-term fasting only, without LCT restriction and MCT
supplementation.5,12 However, the published consensus
guidelines advise that all patients over 12 months of age
should be treated with MCT supplementation.7,8 Since NBS
will not only detect symptomatic but also asymptomatic
individuals, there is an urgent need for early prediction of
the phenotypic severity of the disorder thus allowing person-
alized treatment. Unfortunately, genotype-–phenotype corre-
lation is poor in VLCADD as missense variants of unknown
or uncertain significance are frequent in both the severe and
milder phenotypes.12
Previously, we reported a strong correlation between the
long chain fatty acid oxidation (LC-FAO) flux score
(i.e., the rate of oleate beta-oxidation in cultured skin fibro-
blasts) of VLCADD patients and their clinical outcome.13 In
order to define a dietary strategy for individuals with differ-
ent phenotypes of VLCADD, we retrospectively analyzed
the dietary treatment strategies and clinical outcomes of
patients with VLCADD identified before the introduction of
VLCADD in the Dutch NBS panel and related these data
with the results of LC-FAO flux measurement. Based on this
evaluation we propose a novel dietary strategy for patients
identified with VLCADD by NBS.
2 | SUBJECTS AND METHODS
In the Netherlands, all patients with inherited metabolic dis-
eases are registered in the Dutch Diagnosis Registration
Metabolic Diseases (DDRMD). The DDRMD contains
27 VLCADD patients born before the inclusion of
VLCADD in the Dutch NBS panel in 2007. Of these
patients, four are deceased and for none of them fibroblasts
were available for LC-FAO flux examination. Seven patients
were lost for follow-up. For this study the remaining
16 patients (nine males, seven females) were included with a
median age at inclusion 19.5 years (range 13–45 years).
In the Netherlands, all patients with inherited metabolic dis-
eases are treated and followed up in metabolic centers, located
in six academic hospitals. In addition, patients with FAO disor-
ders are regularly examined in the Dutch FAO expertise center
at the University Medical Center Utrecht by a multidisciplinary
team consisting of a metabolic specialist, a research dietician, a
neurologist, a physical therapists and a cardiologist.
All patients have a confirmed diagnosis based on defi-
cient VLCAD enzymatic activity in lymphocytes and/or cul-
tured fibroblasts and the presence of biallelic mutations in
the ACADVL gene (OMIM 609575).
2.1 | LC-FAO flux score
The LC-FAO flux score in cultured skin fibroblasts was
measured as described previously.13–16 The LC-FAO flux
score is expressed as a percentage of the mean activity
(nanomoles of fatty acid oxidized per hour per milligram of
cellular protein) in healthy control skin fibroblasts measured
in the same experiment. VLCAD enzyme activity in lym-
phocytes is measured as described previously.17 Details of
time and cause of diagnosis, enzyme activity, mutations, and
LC-FAO flux scores are presented in Tables 1 and 2.
2.2 | Nutritional data
Patients completed a 3-day food journal before visiting the
clinic, including two weekdays and one weekend day.
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Information was collected on the maximal feeding pause,
use of medical nutrition and supplements and dietary adjust-
ments during illness or sport. Dietary intake was analyzed
using the Dutch Food Composition Dataset.18 Adjustments
in calories for MCT fat, as this contains 8.3 kcal/g instead of
9 kcal/g for LCT fat, were calculated manually.
2.3 | Clinical severity score (CSS)
We used the severity score as previously described by Diek-
man et al.13 In brief, this score is based on key parameters in
three organ domains: history of hypoglycemia (reported glu-
cose <2.5 mmol/L), cardiac involvement (cardiomyopathy
as documented by abnormal results on echocardiography
with left or right ventricular wall thickness of at least one
segment >2 SD, corrected for age or arrhythmia
(as documented ECG) and myopathy (as documented
CK >250 U/L (ref values 70–170 U/L)) and a history
including at least two of the following symptoms:
myoglobinuria, myalgia, exercise intolerance compared to
age matched reference values, muscle weakness (medical
research council (MRC) grade 4 or less), and/or frequent
fatigue. A score of one point was given for each criterion
(hypoglycemia, cardiac involvement, and myopathy) pre-
sent, resulting in a CSS between 0 and 3.
2.4 | Ethics
The study was approved by the medical ethics committee of
the University Medical Centre Utrecht (METC 10–430). All
patients gave written informed consent for participation in
this study.
2.5 | Statistics
Statistical analyses were performed using IBM SPSS Statis-
tics version 21 (IBM corp., Armonk, NY, USA). The
median is reported for continuous parameters, such as height
TABLE 2 Detailed dietary regimens of included VLCADD patients
PID
Carbohydrates Protein Total fat LCT MCT
Before sports Late night snack
Energy
(kcal) g/day E% g/day E% g/day E% g/day E%
%
total
fat g/day E%
%
total
fat
1 1891 234 49 72 15 80 35 6 3 8 74 32 92 – Modified corn starch
2 1710 221 52 52 12 69 35 32 17 46 37 18 54 Dextrin-maltose Modified corn starch + fat free
tube feeding + MCT
emulsion
3 2357 336 57 109 19 56 20 16 6 30 40 14 70 MCT oil + yoghurt
+fruit, ketone salt 12 g
Modified corn starch +
yoghurt + lemonade syrup
4 1680 144 34 108 26 71 38 14 8 21 57 30 79 – Bread slice + nonfat topping +
yoghurt + MCT oil
5 2250 306 55 76 14 75 30 75 30 100 – – – Nothing specific –
6 1553 173 45 55 17 64 37 64 37 100 – – – – –
7 3958 530 54 131 13 67 15 62 14 93 5 1 7 – 2 Bread slices + nonfat
topping
8 1406 176 50 62 18 52 32 32 20 63 20 12 37 – 1 Tablespoon raw corn starch
9 1544 197 51 69 18 53 31 53 31 100 – – – – –
10 a a a a a a a a a 100 – – – – a
11 1600 241 60 72 18 38 20 21 12 58 17 8 42 Regular meal + MCT oil –
12 2484 317 51 77 12 70 25 70 25 100 – – – Nothing specific –
13 2793 418 60 96 14 76 25 76 25 100 – – – Banana Energy drink
14 1921 230 48 98 20 64 30 64 30 100 – – – Sports drink, currant bun –
15 1928 243 50 74 15 52 24 52 24 100 – – – Gingerbread/ energy bar –
16 2442 385 63 80 13 60 22 60 22 100 – – – – –
aNo recent information.
E% percentage of energy intake, LC-FAO long chain fatty acid oxidation, LCT long chain triglycerides, MCT medium chain triglycerides, PID patient identification
number, VLCADD very long chain acyl-CoA dehydrogenase deficiency.
162 BLEEKER ET AL.
T
A
B
L
E
3
H
ei
gh
t,
w
ei
gh
tc
ha
ra
ct
er
is
tic
s
an
d
di
et
ar
y
re
gi
m
en
s
of
in
cl
ud
ed
V
L
C
A
D
D
pa
tie
nt
s
PI
D
L
C
-F
A
O
flu
x
H
ei
gh
t
W
ei
gh
t
B
od
y
m
as
s
in
de
x
N
oc
tu
rn
al
tu
be
fe
ed
in
g
C
ar
ni
tin
e
L
C
T
re
st
ri
ct
io
n/
M
C
T
su
pp
le
m
en
ta
tio
n
C
ur
re
nt
m
ax
fe
ed
in
g
pa
us
e
(%
of
co
nt
ro
ls
)
(c
m
)
(z
-s
co
re
)
(k
g)
(z
-s
co
re
)
(k
g/
m
2 )
(z
-s
co
re
)
A
ge
st
ar
t
(y
rs
)
A
ge
st
op
(y
rs
)
(m
g/
kg
)
A
ge
st
ar
t
(y
rs
)
A
ge
st
op
(y
rs
)
(h
ou
rs
)
1
5.
6
16
2
−
1.
0
69
.8
+
1.
6
26
.8
+
2.
2
0
15
a
–
0
St
ill
re
st
ri
ct
ed
3
2
5.
9
14
3
−
0.
3
48
.4
+
2.
3
23
.7
+
2.
9
1
St
ill co
nt
in
ue
d
13
.6
0.
3
St
ill
re
st
ri
ct
ed
7
3
6.
1
18
2
0.
0
70
.6
+
0.
4
21
.4
+
0.
5
0
0.
25
–
0
St
ill
re
st
ri
ct
ed
12
4
6.
6
16
7
−
0.
5
57
.0
−
0.
2
20
.4
−
0.
2
0.
1
5
–
0.
1
St
ill
re
st
ri
ct
ed
12
5
29
.5
17
5
+
0.
2
65
.5
+
1.
3
21
.5
+
0.
9
–
–
–
–
–
N
R
6
32
.4
15
9
−
1.
8
90
.5
+
3.
4
35
.8
+
3.
5
–
–
–
2
15
b
N
R
7
32
.7
17
6
−
1.
1
91
.0
+
2.
0
29
.4
+
2.
5
–
–
–
25
St
ill
re
st
ri
ct
ed
8
8
33
18
7
+
0.
5
92
.5
+
2.
1
26
.5
+
1.
8
–
–
–
22
St
ill
re
st
ri
ct
ed
13
9
33
.4
17
5
−
1.
2
72
.0
−
0.
2
23
.5
+
0.
9
–
–
–
–
–
8
10
35
.3
16
6
−
0.
8
93
.0
+
3.
6
34
.0
+
3.
2
–
–
–
0.
75
4
12
11
39
.4
18
7
+
2.
6
94
.0
+
3.
7
26
.9
+
1.
7
–
–
–
1.
5
St
ill
re
st
ri
ct
ed
N
R
12
44
18
6
+
0.
3
83
.0
+
1.
1
24
.0
+
1.
0
–
–
–
–
–
N
R
13
50
.5
18
3
−
0.
1
78
.5
+
0.
6
23
.4
+
0.
8
–
–
–
19
19
12
14
52
.1
19
1
+
2.
0
80
.8
+
2.
3
22
.2
+
1.
4
–
–
–
0
4
11
15
69
.1
18
5
+
0.
2
94
.0
+
2.
2
27
.5
+
2.
1
–
–
–
–
–
8
16
93
15
3
−
2.
8
71
.7
+
1.
5
30
.6
+
2.
6
–
–
–
–
–
N
R
a L
as
ty
ea
rs
w
ith
ou
tn
oc
tu
rn
al
tu
be
fe
ed
in
g,
bu
tc
on
tin
ue
d
ni
gh
tf
ee
ds
.
b L
as
ty
ea
rs
po
or
co
m
pl
ia
nc
e.
LC
-F
A
O
lo
ng
ch
ai
n
fa
tty
ac
id
ox
id
at
io
n,
LC
T
lo
ng
ch
ai
n
tr
ig
ly
ce
ri
de
s,
M
C
T
m
ed
iu
m
ch
ai
n
tr
ig
ly
ce
ri
de
s,
N
R
no
re
st
ri
ct
io
n,
P
ID
pa
tie
nt
id
en
tif
ic
at
io
n
nu
m
be
r,
V
LC
A
D
D
ve
ry
lo
ng
ch
ai
n
ac
yl
-C
oA
de
hy
dr
og
en
as
e
de
fi
ci
en
cy
,y
rs
.
ye
ar
s.
BLEEKER ET AL. 163
and BMI. Reported percentages are the valid percentages,
missing subjects were excluded from the analyses.
3 | RESULTS
3.1 | LC-FAO flux score, dietary treatment,
and clinical severity score
Details on the LC-FAO flux score and clinical outcome are
shown in Tables 1, 3, and Suppl. Table 1.
An LC-FAO flux score of <10% (median: 6.0% (range
5.6–6.6)) was detected in fibroblasts of four patients. All
four had been on nocturnal gastric drip feeding during their
early years of life and were still on a strict diet containing
<20 energy percent (E%) LCT supplemented with MCT,
with a limited maximal feeding pause (Tables 2 and 3). All
four had a CSS of 3. In addition, they still had recurrent
symptoms and were frequently hospitalized for metabolic
crises. Finally, all had or had had adjusted school schedules
or were unemployed because of health issues.
In contrast, the one patient with an LC-FAO flux score of
>90% had no symptoms (CSS of 0), had not used any die-
tary treatment, and followed general education.
The 11 patients with LC-FAO flux scores between
10 and 90% showed a more heterogeneous phenotype. In
this group, we did not find a correlation between LC-FAO
flux score and CSS. LCT restriction and MCT supplementa-
tion had been started in seven patients, and three were still
on this diet at the time of this study. In this cohort, all
patients with a calculated daily intake of LCT ≤20 E%
(3–20 E%, n = 7) are supplemented with MCT (1–32 E%)
(Table 2). Four patients returned to a normal diet after initial
LCT restriction and MCT supplementation on their own
(n = 2) or doctor’s initiative after an asymptomatic period
(Table 3).
We were able to phase out MCT in two asymptomatic
patients without adverse events. Reducing MCT was done
stepwise with either home controlled monitoring or hospital
controlled monitoring of CK and acylcarnitines. As an
example, patient 14, was supplemented with MCT until the
age of 4, but MCT dose was gradually reduced in steps of
2 weeks with 5% decrease of dosage and weekly monitoring
of CK and acylcarnitine profiles (mother took blood at
home). No clinical deterioration was observed and the fam-
ily reported a serious improvement in quality of life when
dietary restrictions were alleviated. It is not possible to corre-
late this to clinical outcome, because the patients were
already in a good clinical condition when MCT was
reduced.
In contrast, the severe patients who are currently still on
an LCT-restricted/MCT-supplemented diet experience
symptoms on a regular basis. We have never deliberately
tried to reduce the amount of MCT in these patients.
3.2 | Fasting period
Eight of the 16 included patients were treated with either a
late night snack, MCT, raw or modified corn starch
(Glycosade®, Nestlé Health Science) or nocturnal tube feed-
ing in order to decrease the maximum fasting period
(Tables 2 and 3). Of the seven patients who used MCT sup-
plementation, six (86%) also used a late night snack, raw or
FIGURE 1 Dutch guideline for infants diagnosed with VLCADD by NBS before LC-FAO flux score is known. ASAT, aspartate
aminotransferase; ALAT, alanine aminotransferase; CK, creatine kinase; E%, energy percentage; LC-FAO flux, long chain fatty acid oxidation flux;
MCT, medium chain triglycerides; NBS, newborn screening; VLCADD, very long chain acyl-CoA dehydrogenase deficiency
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modified corn starch and/or nocturnal tube feeding. Raw or
modified corn starch was used by two (25%) of the patients
and nocturnal tube feeding was used by one patient.
3.3 | Dietary intervention during illness
During illnesses the majority of patients (12 out of 16)
adjusted their regular diet. Nine (56%) shortened their maxi-
mum feeding pause. In addition, three used extra carbohy-
drates (e.g., dextrin maltose) as supplement and lowered
overall fat intake, one added MCT to the diet during illness,
and one patient started continuous gastric drip feeding.
3.4 | Dietary interventions before or during
sports
Of the eight patients that practiced sports (Table 1), five
used dietary interventions before or during sports (Table 2).
Three of them shortened their maximum feeding pause by
eating or drinking carbohydrate-rich refreshment before or
during sports. One patient added a source of carbohydrates
(e.g., dextrin-maltose, Fantomalt®, Nutricia) to his diet and
one used a source of MCT before sports.
3.5 | Height and weight
Table 3 shows height, weight, and body mass index of the
included VLCADD patients. The median height of the six
male patients (age: ≥18 years) was 184 cm (range: 175–187)
and is comparable to the mean of the height of the Dutch
male population (180.7 cm). The median height of the
female patients (age: ≥18 years) was 166 cm (153–187 cm,
n = 5). The mean height in the adult Dutch female popula-
tion is 167.2 cm.19
There was a large variation in BMI. In the patients youn-
ger than 18 years (n = 5; three male, two female) the median
Z-score for BMI20 was 1.4 (−0.5 − +2.9). In adult patients
(n = 11; six male, five female), eight out of 11 were classi-
fied as overweight with a BMI >25.0 kg/m2 of which three
patients had obesity with a BMI >30.0 kg/m2. No correla-
tion was found between weight and LC-FAO flux score.
Median Z-score for BMI was higher in patients that were on
LCT restriction/MCT supplementation compared to those
that were not (+2.0 vs +1.2), but this was not significant
and no correlation of BMI and LC-FAO flux score could be
found in either group (Suppl. Fig. 1a–b). Median Z-score for
BMI was lower in patients that practiced sports compared to
those that did not (+1.2 vs +2.35), but the difference was
not significant and no correlation of BMI and LC-FAO flux
score could be found in either group (Suppl. Fig. 1c–d).
3.6 | Genotype
All patients with homozygous loss-of-function mutations in
ACADVL, such as frameshift and splice-site mutations, had
an LC-FAO flux score <10% (supplementary Table 1). Five
patients were compound heterozygous for one missense and
one loss-of-function mutation and all of them had an LC-
FIGURE 2 Dutch guideline for infants diagnosed with VLCADD by NBS when LC-FAO flux score is known. E%, percentage of energy
intake; LC-FAO, long chain fatty acid oxidation; MCT, medium chain triglycerides; NBS, newborn screening; VLCADD, very long chain acyl-CoA
dehydrogenase deficiency
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FAO flux score between 10 and 90%. At diagnosis, most
patients had a combination of different missense mutations
with unknown effect on the protein. Therefore, genotyping
would be insufficient to predict phenotype; hence, the
requirement of enzymatic assays, such as VLCAD activity
and LC-FAO flux.
4 | DISCUSSION
This study shows that the LC-FAO flux score is a good pre-
dictor of clinical outcome in VLCADD patients identified
before introduction of this disorder in the NBS panel. Fur-
thermore, a poor clinical outcome could not be prevented by
dietary intervention, comprising LCT restriction or MCT
supplementation and all patients with a low LC-FAO flux
score (<10%) had severe VLCADD-related symptoms
despite the use of intensive dietary treatment. VLCADD
patients with an intermediate LC-FAO flux score (between
10 and 90%) received different dietary interventions and had
variable outcomes which seemed unrelated to their LCT and
MCT intake. The one individual with a high LC-FAO score
(>90%) had an excellent outcome without any dietary
intervention.
The observation that not all VLCADD patients need die-
tary treatment, including the use of MCT, has been reported
previously.21–23 However, in two studies,21,23 patients were,
in contrast to our cohort, identified by NBS and treated with
MCT until the age of 5 years. It may be possible that a
severely LCT-restricted diet might have negative clinical
consequences, for example on essential fatty acids.24 More-
over, there is also evidence that MCT supplementation can
be harmful as MCT might be elongated to LCT in certain
circumstances.25–28 Based on our findings we cannot con-
clude anything on these matters as we did not find any corre-
lation between the amount of MCT and clinical symptoms.
In addition, LCT-restriction and MCT-supplementation was
only stopped in patients who were asymptomatic. There is
one report describing the disastrous effect of accidental LCT
loading in a patient who normally used MCT. However, of
course, there is a difference between LCT loading and nor-
mal intake.29
Prediction of phenotypic severity based only on mutation
analysis is often not feasible in VLCADD,12 which is con-
firmed by the present study. Biallelic loss-of-function muta-
tions that have a severe effect on protein function, such as
splice-site and frameshift mutations, clearly result in a very
low LC-FAO flux score and poor outcome. However, this
concerns only a small subset of patients. The majority of
patients are compound heterozygous for different combina-
tions, including missense mutations. The consequences of
such combinations of different mutations on VLCAD
enzyme activity and the flux through the pathway cannot be
predicted, and this can only be assessed by studies in cul-
tured skin fibroblasts. We previously showed that the LC-
FAO flux score, an established method that has been used
for several years,14–16 appears to be the best parameter in
predicting the clinical severity.13 Hence, we suggest that the
LC-FAO flux score in fibroblasts can be used as a method
for selecting the optimal therapeutic strategy. In patients
with an LC-FAO flux score >90%, the VLCADD can prob-
ably be best considered as a ‘risk factor’, which will only
lead to clinical symptoms after significant provocation, such
as prolonged fasting during an infection. In our opinion there
is no need for these patients to use a continuous dietary treat-
ment. Since patients with an LC-FAO flux score <10% have
severe clinical symptoms even despite a strict dietary treat-
ment, there is a need for alternative treatment options for
these patients. However, we cannot advise to refrain from
dietary intervention in this group. Indeed, anecdotal evi-
dence suggests that stopping the diet in patients with a
severe phenotype may have deleterious clinical
consequences.29
In patients with an LC-FAO flux score in fibroblasts
between 10 and 90%, a dietary strategy, based on the clinical
course of the disease is probably the best option. It is clear
that the ordinal inclusion of hypoglycemia in the CSS
obscures the correlation between clinical severity and LC-
FAO flux score, especially in the group with an LC-FAO
flux score between 10 and 90%. Still, CSS correlates better
to LC-FAO flux score than myopathy in this group (Suppl.
Fig. 2). Due to this disadvantage, we do not yet propose to
use the LC-FAO flux score to distinguish within the 10–90%
LC-FAO flux score group, but we strongly feel that it is
already a useful tool to distinguish between severe and mild
patients and avoid stringent dietary measures in individuals
with sufficient beta-oxidation.
A limitation of this study is that patients were treated in dif-
ferent centers, which is probably why some patients with an
intermediate flux were treated more aggressively than others.
In this group, different approaches along with clinical course of
the disease have both attributed to the variety in this group.
Based on our findings, we propose a treatment strategy
for individuals with VLCADD identified by NBS, which is
shown in Figures 1 and 2. This strategy has been approved
by the advisory board for NBS on inborn errors in the Neth-
erlands and is currently implemented within the Dutch NBS
program. Since the LC-FAO flux score can only be mea-
sured in fibroblasts it will take at least 3 months before these
results are known. While waiting for these results, a maxi-
mum feeding pause and emergency advice during illness are
prescribed (Figure 1). If a child is clinically ill when the
diagnosis is made, fat intake should be stopped immediately
until the child is clinically stable. Caution is warranted if this
exceeds 24 h as caloric intake should also be adequate to
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prevent a catabolic state. Clinical symptoms in this stage
immediately result in an LCT-restricted/MCT-supplemented
diet. If a patient is asymptomatic after diagnosis, but has a
significantly elevated creatine kinase or amino transferases
(Figure 1), the patient will receive an LCT-restricted/MCT-
supplemented diet, with a total fat restriction (25–30 E%).
The initial dietary restrictions can be alleviated when the
child is clinically stable for a longer period of time and LC-
FAO flux score is sufficient (Figure 2).
If LCT restriction/MCT supplementation needs to be
started, we advise to follow the recommended guidelines for
healthy nutrition and keep caloric intake and carbohydrate
intake appropriate for age. Regarding BMI control, weight
loss should only be done under strict monitoring and depen-
dent on individual needs. There has been a report in litera-
ture about monitored weight loss in patients with long-chain
fatty acid oxidation disorders.30
If a patient is asymptomatic after diagnosis and has
normal lab findings (Figure 1) the feeding of the baby can
continue as normal, including breastfeeding, but there
are strict limitations regarding the maximal feeding
pause depending on age. During illness, dietary adjust-
ments such as frequent carbohydrate-rich feedings are
commenced.
With regard to the future, since VLCADD has been intro-
duced in many newborn screening programs worldwide,
more patients will be detected from an early age. Most
likely, the majority of patients identified by NBS will have
LC-FAO flux scores >10%.
The nationwide implementation of the LC-FAO flux score
will allow us to test the validity of the proposed strategy in
VLCADD patients diagnosed by NBS and probably define
better cut-off values for dietary adjustments in the future.
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